Solid Biosciences shifts Ilan Ganot to Class I director role in board reshuffle

Solid Biosciences Inc.

Solid Biosciences Inc.

SLDB

0.00
  • Solid Biosciences shifted director Ilan Ganot from Class III to Class I, effective 4 p.m. ET on April 10, 2026.
  • Change rebalanced board classes; Class III directors reduced to three, Class I directors increased to three.
  • Ganot’s Class I term runs through 2028 annual meeting; he will not stand for election at 2027 annual meeting.
  • Company plans an advisory stockholder ratification vote on Ganot’s Class I appointment at 2026 annual meeting.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Solid Biosciences Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-151259), on April 10, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.